Purine Analogs in Lymphoproliferative Disorders

References

• Cheson B. D. New antimetabolites in the treatment of human malignancies. Semin. Oncol. 1992; 19: 695–706
   PubMed Web of Science ®Google Scholar
• Carson D. A., Wasson D. B., Esparza L. M., Carrera C. J., et al. Oral antilymphocyte activity and induction of apoptosis by 2–chloro-2′-arabino-fluoro-2′-deoxyadenosine. Proc. Natl. Acad Sci. 1992; 89: 2970–2974
   PubMed Web of Science ®Google Scholar
• Robertson L., Chubb S., Hittelman W. N., Sandoval A., et al. Programmed death (apoptosis) in chronic lymphocytic leukemia cells after fludarabine and chlorodeoxyadenosine. Blood 1991; 78(suppl. 1)173a, abstr 682
   Google Scholar
• Carrera C. J., Piro L. D., Saven A., Beutler E., . 2–Chlorodeoxyadenosine chemotherapy triggers programmed cell death in normal and malignant lymphocytes. Purine and Pyrimidine Metabolism in Man, R. A. Harkness, et al. Plenum Press, New York 1991; 15–18
   Google Scholar
• Robertson L. E., Chubb S., Meyn R. E., Story M., et al. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2–chloro-2′-deoxyadenosine and 9–β-D-arabinosyl fluoroadenine. Blood 1993; 81: 143–150
   PubMed Web of Science ®Google Scholar
• Grever M. R., Leiby J. M., Kraut E. H., Wilson H. E., et al. Low-dose deoxycoformycin in lymphoid malignancy. J. Clin. Oncol. 1985; 3: 1196–1201
   PubMed Web of Science ®Google Scholar
• Cheson B. D., Bennett J. M., Rai K. R., Grever M. R., et al. Guidelines for clinical protocols for chronic lymphocytic leukemia: Report of the NCI-sponsored Working Group. Am. J. Hematol. 1988; 29: 152–163
   PubMed Web of Science ®Google Scholar
• Keating M. J. Fludarabine monophosphate in the treatment of chronic lymphocytic leukemia. Semin. Oncol. 1990; 17: 49–62
   PubMed Web of Science ®Google Scholar
• Keating M. J., Kantarjian H., O'Brien S., Koller C., et al. Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J. Clin. Oncol. 1991; 9: 44–49
   PubMed Web of Science ®Google Scholar
• O'Brien S., Kantarjian H., Koller C., Robertson L., et al. Fludarabine-prednisone: a highly effective regimen in chronic lymphocytic leukemia (CLL). Proc. Am. Soc. Clin. Oncol. 1992; 11: 260, abstr 850
   Google Scholar
• Sorenson J. M., Vena D., Fallavollita A., Cheson B. D. Treatment of refractory chronic lymphocytic leukemia (CLL) with fludarabine monophosphate (FAMP). Proc. Ant. Soc. Clin. Oncol. 1992; 11: 264, abstr 867
   Google Scholar
• Hiddemann W., Rottmann R., Wormann B., Thiel A., et al. Treatment of advanced chronic lymphocytic leukemia by fludarabine. Results of a clinical phase-II study. Ann. Hematol. 1991; 63: 1–4
   PubMed Web of Science ®Google Scholar
• Whelan J. S., Davis C. L., Rule S., Ranson M., et al. Fludarabine phosphate for the treatment of low grade lymphoid malignancy. Br. J. Cancer 1991; 64: 120–123
   PubMed Web of Science ®Google Scholar
• Puccio C. A., Mittelman A., Lichtman S. M., Silver R. T., et al. A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia. J. Clin. Oncol. 1991; 9: 1562–1569
   PubMed Web of Science ®Google Scholar
• Robertson L. E., O'Brien S., Koller C., Beran M., et al. A three-day schedule of fludarabine in chronic lymphocytic leukemia (CLL). Blood 1992; 80(suppl. 1)47a, abstr 177
   Google Scholar
• Grever M. R., Kopecky K. J., Coltman C. A., Files J. C., et al. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv. Rev. Fr. Hematol. 1988; 30: 457–459
   PubMedGoogle Scholar
• Cheson B. D., Vena D. A., Sorenson J. M., Fallavollita A. Current status of U.S. clinical trials in chronic lymphocytic leukemia. Leukemia and Lymphoma 1991; 5: 119–122
   PubMed Web of Science ®Google Scholar
• Saven A., Carrera C. J., Carson D. A., Beutler E., et al. 2–Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leukemia and Lymphoma 1991; 5: 133–138
   PubMed Web of Science ®Google Scholar
• Juliusson G., Liliemark J. High complete remission rate from 2–chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: Response predicted by rapid decrease in blood lymphocyte count. J. Clin. Oncol. 1993; 11: 679–689
   PubMed Web of Science ®Google Scholar
• O'Dwyer P. J., Wagner B., Leyland-Jones B., Wittes R. E., et al. 2′-Deoxycoformycin (pentostatin) for lymphoid malignancies. Ann. Intern. Med. 1988; 108: 733–743
   PubMed Web of Science ®Google Scholar
• Dillman R. O., Mick R., McIntyre O. R. Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia Group B. J. Clin. Oncol. 1989; 7: 433–438
   PubMed Web of Science ®Google Scholar
• Ho A. D., Thaler J., Strykmans P., Coiffier B., et al. Pentostatin in refractory chronic lymphocytic leukemia: A phase II trial of the European Organization for Research and Treatment of Cancer. J. Natl. Cancer Inst. 1990; 82: 1416–1420
   PubMed Web of Science ®Google Scholar
• Robertson L. E., Huh Y. O., Butler J. J., Pugh W. C., et al. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Blood 1992; 80: 29–36
   PubMed Web of Science ®Google Scholar
• Juliusson G., Elmhorn-Rosenborg A., Liliemark J. Complete response to 2–chloro-2′-deoxyadenosine (CDA) in B-cell chronic lymphocytic leukemia resistant to fludarabine. N. Engl. J. Med. 1992; 327: 1056–1061
   PubMed Web of Science ®Google Scholar
• Saven A., Lemon R. H., Piro L. D. 2–chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N. Engl. J. Med. 1993; 328: 812–813, (letter)
   PubMed Web of Science ®Google Scholar
• Delannoy A., Hanique G., Ferrant A. 2–Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N. Engl. J. Med. 1993; 328: 812, letter
   PubMed Web of Science ®Google Scholar
• Dearden C., Catovsky D. Deoxycoformycin in the treatment of mature B-cell malignancies. Br. J. Cancer 1990; 62: 4–5
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Childs C., O'Brien S., Huh Y., et al. Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia. Am. J. Med. 1991; 90: 223–228
   PubMed Web of Science ®Google Scholar
• Zinzani P. L., Rondelli D., Lauria F., Raspadori D., et al. Fludarabine: an effective drug in refractory lymphoproliferative disorders. Proc. Am. Soc. Clin. Oncol. 1992; 11: 268, abstr 881
   Google Scholar
• Cervantes F., Slagado C., Montserrat E., Rozman C. Fludarabine for prolymphocytic leukemia and risk of interstitial pneumonitis. Lancet 1990; 336: 1130–1131
   PubMed Web of Science ®Google Scholar
• Sporn J. R. Sustained response of refractory prolymphocytic leukemia to fludarabine. Acta Haematol. 1991; 85: 209–211
   PubMed Web of Science ®Google Scholar
• Dohner H., Ho A. D., Thaler J., Stryckmans P., et al. Pentostatin in prolymphocytic leukemia: Phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group. J. Natl. Cancer Inst. 1993; 85: 658–662
   PubMed Web of Science ®Google Scholar
• Durrleman S., Grem J. L., Cheson B. D. 2′-deoxycoformycin after failure of alpha-interferon in hairy cell leukemia. Eur. J. Haematol. 1989; 43: 297–302
   PubMed Web of Science ®Google Scholar
• Estey E. H., Kurzrock R., Kantarjian H. M., O'Brien S. M., et al. Treatment of hairy cell leukemia with 2–chlorodeoxyadenosine (2–CdA). Blood 1992; 79: 882–887
   PubMed Web of Science ®Google Scholar
• Tallman M., Hakimian D., Variakojis D., Kaul K., et al. 2–Chlorodeoxyadenosine (2–CDA) in the treatment of hairy cell leukemia (HCL). Blood 1991; 78(suppl. 1)34a, abstr 127
   Google Scholar
• Lauria F., Benfenati D., Zinzani P. L., Raspadori D., et al. 2–chlorodeoxyadenosine in the treatment of hairy cell leukemia patients relapsed after alpha-IFN. Blood 1991; 78(suppl. 1)34a, abstr 128
   Google Scholar
• Piro L. D., Carrera C. J., Carson D. A., Beutler E. Lasting remissions in hairy cell leukemia induced by a single infusion of 2–chlorodeoxyadenosine. N. Engl. J. Med. 1990; 322: 1117–1121
   PubMed Web of Science ®Google Scholar
• Hoffman M., Rai K., Janson D., Kubik B., et al. Comparison of complete remission (CR) rates among previously treated or untreated hairy cell leukemia (HCL) patients (PTS) with 2–chlorodeoxyadenosine (CdA). Proc. Am. Soc. Clin. Oncol. 1992; 11: 271, abstr 895
   Google Scholar
• Grever M., Kopecky K., Head D., Cassileth P., et al. A randomized comparison of deoxycoformycin (DCF) versus alpha-2a interferon (IFN) in previously untreated patients with hairy cell leukemia (HCL): An NCI-sponsored intergroup study (SWOG, ECOG, CALGB, NCIC CTG). Proc. Am. Soc. Clin. Oncol. 1992; 11: 264, abstr 868
   Google Scholar
• Saven A., Piro L. D. Treatment of hairy cell leukemia. Blood 1992; 79: 1111–1120
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Schachner J., Keating M. J. Fludarabine therapy in hairy cell leukemia. Cancer 1991; 67: 1291–1293
   PubMed Web of Science ®Google Scholar
• Kraut E. H., Chun H. G. Fludarabine phosphate in refractory hairy cell leukemia. Am. J. Hematol. 1991; 37: 59–60
   PubMed Web of Science ®Google Scholar
• Johnston J. B., Glazer R. I., Pugh L., Israels L. G. The treatment of hairy-cell leukemia with 2′-deoxycoformycin. Br. J. Haematol. 1986; 63: 525–534
   PubMed Web of Science ®Google Scholar
• Kraut E. H., Bouroncle B. A., Grever M. R. Pentostatin in the treatment of advanced hairy cell leukemia. J. Clin. Oncol. 1989; 7: 168–172
   PubMed Web of Science ®Google Scholar
• Ho A. D., Thaler J., Mandelli F., Lauria F., et al. Response to pentostatin in hairy-cell leukemia refractory to interferon-alpha. J. Clin. Oncol. 1989; 7: 1533–1538
   PubMed Web of Science ®Google Scholar
• Cassileth P. A., Cheuvart B., Spiers A. S. D., Hanington D. P., et al. Pentostatin induces durable remissions in hairy cell leukemia. J. Clin. Oncol. 1991; 9: 243–246
   PubMed Web of Science ®Google Scholar
• Piro L. D., Saven A., Ellison D., Beutler E. Prolonged complete remissions following 2–chlorodeoxyadenosine (2–CdA) in hairy cell leukemia (HCL). Proc. Am. Soc. Clin. Oncol. 1992; 11: 259, abstr 846
   Google Scholar
• Juliusson G., Liliemark J. Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2–chloro-2′deoxyadenosine (CdA): Relation to opportunistic infections. Blood 1992; 79: 888–894
   PubMed Web of Science ®Google Scholar
• Hochster H. S., Kim K., Green M. D., Mann R. B., et al. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: Results of an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 1992; 10: 28–32
   PubMed Web of Science ®Google Scholar
• Redman J. R., Cabanillas F., Velasquez W. S., MC-Laughlin P., et al. Phase II trial of fludarabine phosphate in lymphoma: An effective new agent in low-grade lymphoma. J. Clin. Oncol. 1992; 10: 790–794
   PubMed Web of Science ®Google Scholar
• Kay A. C., Saven A., Carrera C. J., Piro L. D. 2–Chlorodeoxyadenosine treatment of low-grade lymphomas. J. Clin. Oncol. 1992; 10: 371–377
   PubMed Web of Science ®Google Scholar
• Grever M. R., Siaw M. F. E., Jacob W. F., Neidhart J. A., et al. The biochemical and clinical consequences of 2′-deoxycoformycin in refractory lymphoproliferative malignancy. Blood 1981; 57: 406–417
   PubMed Web of Science ®Google Scholar
• Duggan D. B., Anderson J. R., Dillman R., Case D., et al. 2′Deoxycoformycin (pentostatin) for refractory non-Hodgkin's lymphoma: A CALGB phase II study. Med. Ped. Oncol. 1990; 18: 203–206
   PubMedGoogle Scholar
• Cummings F. J., Kim K., Neiman R. S., Comis R. L., et al. Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease. J. Clin. Oncol. 1991; 9: 565–571
   PubMed Web of Science ®Google Scholar
• Dimopoulos M., Kantarjian H. M., Estey E., O'Brien S., et al. 2–Chlorodeoxyadenosine (2CDA) is an effective treatment for Waldenstrom's macroglobulinemia. Blood 1992; 80(suppl. 1)159a, abstr 625
   Google Scholar
• Kantarjian H. M., Redman J. R., Keating M. J. Fludarabine phosphate in other lymphoid malignancies. Semin. Oncol. 1990; 17: 66–70
   PubMed Web of Science ®Google Scholar
• Dimopoulos M. A., Kantarjian H. M., Estey E. 2–Chlorodeoxyadenosine in the treatment of multiple myeloma. Blood 1992; 80: 1626
   PubMed Web of Science ®Google Scholar
• Belch A. R., Henderson J. F., Brox L. W. Treatment of multiple myeloma with deoxycoformycin. Cancer Chemother. Pharmacol. 1985; 14: 49–52, R. A.
   PubMed Web of Science ®Google Scholar
• Grever M. R., Crowley J., Salmon S., McGee R., et al. Phase II investigation of pentostatin in multiple myeloma: A Southwest Oncology Group study. J. Natl. Cancer Inst. 1990; 82: 1778–1779
   PubMed Web of Science ®Google Scholar
• Kraut E. H., Crowley J. J., Grever M. R., Keppen M. D., et al. Phase II study of fludarabine phosphate in multiple myeloma. Invest. New Drugs 1990; 8: 199–200
   PubMed Web of Science ®Google Scholar
• Lichtman S. M., Mittelman A., Budman D. R., Puccio C. A., et al. Phase II trial of fludarabine phosphate in multiple myeloma using a loading dose and continuous infusion. Leukemia and Lymphoma 1991; 6: 61–63
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Alexanian R., Koller C. A., Kurzrock R., et al. Fludarabine therapy in macroglobulinemic lymphoma. Blood 1990; 75: 1928–1931
   PubMed Web of Science ®Google Scholar
• Beutler E. Cladribine (2–chlorodeoxyadenosine). Lancet 1992; 340: 952–956
   PubMed Web of Science ®Google Scholar
• Riddell S., Johnston J. B., Rayner H. L., Israels L. G. Response of Waldenstrom's macroglobulinemia to pentostatin (2′-deoxycoformycin). Cancer Treat. Rep. 1985; 70: 546–548
   Google Scholar
• Dearden C., Matutes E., Catovsky D. Deoxycofonnycin in the treatment of mature T-cell leukemias. Br. J. Cancer 1991; 64: 903–906
   PubMed Web of Science ®Google Scholar
• Grever M. R., Bisaccia E., Scarborough D. A., Metz E. N., et al. An investigation of 2′deoxycoformycin in the treatment of cutaneous T-cell lymphoma. Blood 1983; 61: 279–282
   PubMed Web of Science ®Google Scholar
• Grever M. R., Chapman R. A., Ratanatharathorn V., Slease R. B. An investigation of deoxycoformycin in advanced cutaneous T cell lymphoma (CTCL). Blood 1985; 66(suppl. 1)215a, abstr 744
   Google Scholar
• Saven A., Camera C. J., Carson D. A., Beutler E., et al. 2–chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood 1989; 74(suppl. 1)239a, abstr 896
   Google Scholar
• Von Hoff D. D., Dahlberg S., Hartsock R. J., Eyre H. J. Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: A Southwest Oncology Group study. J. Natl. Cancer Inst. 1990; 82: 1353–1355
   PubMed Web of Science ®Google Scholar
• Carson D. A., Wasson D. B., Beutler E. Antileukemic and immunosuppressive activity 'of 2–chloro-2′-deoxyadenosine. Proc. Natl. Acad. Sci. 1984; 81: 2232–2236
   PubMed Web of Science ®Google Scholar
• Daenen S., Rojer A., Smit J. W., Halie M. R., et al. Successful chemotherapy with deoxycoformycin in adult T-cell lymphoma-leukemia. Br. J. Haematol. 1984; 58: 723–727
   PubMed Web of Science ®Google Scholar
• Lofters W., Campbell M., Gibbs W. N., Cheson B. D. 2′-Deoxycoformycin therapy in adult T-cell leukemia/lymphoma. Cancer 1987; 60: 2605–2608
   PubMed Web of Science ®Google Scholar
• Yamaguchi K., Yul L. S., Oda T., Maeda Y., et al. Clinical consequences of Z'deoxycoformycin treatment in patients with refractory adult T-cell leukemia. Leuk. Res. 1986; 10: 989–993
   PubMed Web of Science ®Google Scholar
• Estey E., Freireich E., Koller C., Piro L., et al. Treatment of advanced, refractory T-cell CLL with 2–chlorodeoxyadenosine (2CdA). Proc. Am. Assoc. Cancer Res. 1990; 31: 191, abstr 1138
   Google Scholar
• Chun H. G., Leyland-Jones B., Cheson B. D. Fludarabine phosphate: A synthetic purine antimetabolite with significant activity against lymphoid malignancies. J. Clin. Oncol. 1991; 9: 175–188
   PubMed Web of Science ®Google Scholar
• Saven A., Piro L. D. Phase I trial of 2–chlorodeoxyadenosine in solid tumors. J. Clin. Oncol. 1993; 11: 671–678
   PubMed Web of Science ®Google Scholar
• O'Dwyer P. J., Spiers A. S. D., Marsoni S. Association of severe and fatal infections and treatment with pentostatin. Cancer Treat. Rep. 1986; 70: 1117–1120
   PubMedGoogle Scholar
• Anaissie E., Kontoyiannis D. P., Kantarjian H., Elting L., et al. Listeriosis in patients with chronic lymphocytic Ieukemia who are treated with fludarabine and prednisone. Ann. Intern. Med. 1992; 117: 466–469
   PubMed Web of Science ®Google Scholar
• Chun H. G., Leyland-Jones B. R., Caryk S. M., Hoth D. F. Central nervous system toxicity of fludarabine phosphate. Cancer Treat. Rep. 1986; 70: 1225–1228
   PubMedGoogle Scholar
• Spriggs D. R., Stopa E., Mayer R. J., Schoene W., et al. Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: Phase I and neuropathological study. Cancer Res. 1986; 46: 5953–5958
   PubMed Web of Science ®Google Scholar
• Casper E. S., Mittelman A., Kelson D., Young C. W. Phase I clinical trial of fludarabine phosphate (Fara-AMP). Cancer Chemother. Pharmacol. 1985; 15: 233–235
   PubMed Web of Science ®Google Scholar
• Wanell R. P., Jr., Berman E. Phase I and II study of fludarabine phosphate in leukemia: Therapeutic efficacy with delayed central nervous system toxicity. J. Clin. Oncol. 1986; 4: 74–79
   PubMed Web of Science ®Google Scholar
• Schilling P. J., Vadhan-Raj S. Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia. N. Engl. J. Med. 1990; 323: 833–834, letter
   PubMed Web of Science ®Google Scholar
• El'Agnaf M. R., Ennis K. E., Moms T. C. M., Robertson J. H., et al. Successful remission induction with deoxycoformycin in elderly patients with T-helper prolymphocytic leukemia. Br. J. Haematol. 1986; 63: 93–104
   PubMed Web of Science ®Google Scholar
• Kane G. C., McMichael A. J., Patrick H., Erslev A. J. Pulmonary toxicity and acute respiratory failure associated with fludarabine monophosphate. Resp. Med. 1992; 86: 261–263
   PubMed Web of Science ®Google Scholar
• Cohen R. B., Abdallah J. M., Gray J. R., Foss F. Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia. Ann. Intern. Med. 1993; 118: 114–116
   PubMed Web of Science ®Google Scholar
• Spielberger R. T., Stock W., Larson R. A. Listeriosis after 2–chlorodeoxyadenosine treatment. N. Engl. J. Med. 1993; 328: 813–814
   PubMed Web of Science ®Google Scholar
• Hurst P. G., Habib M., Garewal H., Bluestein M., et al. Pulmonary toxicity associated with fludarabine monophosphate. Invest. New Drugs 1987; 5: 207–210
   PubMed Web of Science ®Google Scholar
• List A. F., Kummet T. D., Adams J. D., Chun H. G. Tumor lysis syndrome complicating treatment of chronic lymphocytic leukemia with fludarabine phosphate. Am. J. Med. 1990; 89: 388–390
   PubMed Web of Science ®Google Scholar
• Merkel D. E., Griffin N. L., Kagan-Hallet K., Von Hoff D. D. Central nervous system toxicity with fludarabine. Cancer Treat. Rep. 1986; 70: 1449–1450
   PubMedGoogle Scholar
• Bernard S., Gill P., Rosen P., Gavigan M., et al. A phase I trial of alpha-interferon in combination with pentostatin in hematologic malignancies. Med. Ped. Oncol. 1991; 19: 276–282
   PubMedGoogle Scholar
• Elias L., Stock-Novak D., Grever M., Weick J., et al. A phase I trial of combination fludarabine and chlorambucil in chronic lymphocytic leukemia. Proc. Am. Soc. Clin. Oncol. 1991; 10: 221, abstr 745
   Google Scholar
• Weiss M., Kempin S., Berman E., Eardley A., et al. Results of a phase I study of fludarabine phosphate (FAMP) plus chlorambucil (CLB) in patients with chronic lymphocytic leukemia. Proc. Am. Soc. Clin. Oncol. 1992; 11: 276, abstr 914
   Google Scholar
• Foss F., Fischmann A., Schechter G., Ihde D., et al. Phase II trial of human interferon-alfa-2A and pentostatin in advanced stage mycosis fungoides/Sezary syndrome. Proc. Am. Soc. Clin. Oncol. 1990; 9: 259, abstr 1005
   Google Scholar
• Foss F., Ihde D., Phelps R., Fischmann A., et al. Phase II(study of fludarabine and interferon-alfa-2A in advanced mycosis fungoides/Sezary syndrome (MF/SS). Proc. Am. Soc. Clin. Oncol. 1992; 11: 315, abstr 1068
   Google Scholar
• Gandhi V., Nowak B., Keating M. J., Plunkett W. Modulation of arabinosylcytosine metabolism by arabinosyl-2–fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: Implications for combination therapy. Blood 1989; 74: 2070–2075
   PubMed Web of Science ®Google Scholar
• Gandhi V., Estey E., Keating M. J., Plunkett W. Synergistic combination of fludarabine and ara-C for AML therapy. Blood 1991; 78(suppl. 1)52a, abstr 198
   Google Scholar
• Haberman T. M., Andersen J. W., Cassileth P. A., Bennett J. M., Oken M. M. Sequential administration of recombinant interferon alpha and deoxycoformycin in the treatment of hairy cell leukemia. Br. J. Haematol. 1992; 80: 466–471
   PubMed Web of Science ®Google Scholar
• Dameshek W. Chronic lymphocytic leukemia—an accumulative disease of immunologically incompetent lymphocytes. Blood 1967; 29: 566
   PubMed Web of Science ®Google Scholar
• Miyashita T., Reed J. C. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993; 81: 151–157
   PubMed Web of Science ®Google Scholar